Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BREO ELLIPTA vs AEROSEB-HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema,Maintenance treatment of asthma in patients aged 18 years and older
FDA-approved for the treatment of eczematous dermatitis, atopic dermatitis, and other glucocorticoid-responsive dermatoses complicated by fungal or bacterial infections
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
Fluticasone furoate: primarily metabolized by CYP3A4; Vilanterol: primarily metabolized by CYP3A4.
Hydrocortisone is primarily hepatic via CYP3A4; iodoquinol is not extensively metabolized, with partial glucuronidation and enterohepatic circulation.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Fluticasone furoate: >99.8% (primarily albumin). Vilanterol: approximately 94% (albumin and alpha-1-acid glycoprotein).
90-95% (albumin and corticosteroid-binding globulin).
Fluticasone furoate: approximately 4.5 L/kg (extensive tissue distribution). Vilanterol: approximately 165 L (large Vd, extensive distribution).
0.4-0.6 L/kg; indicates distribution into total body water and tissues.
Inhaled: Fluticasone furoate absolute bioavailability approximately 15% (lung deposition). Vilanterol absolute bioavailability approximately 27% (lung deposition). Oral bioavailability is negligible for both (<2% for fluticasone furoate, <5% for vilanterol).
Oral: 80-90%; Intramuscular: 100%; Intravenous: 100%.
No dosage adjustment required for renal impairment. However, use with caution in severe renal impairment due to potential for increased systemic exposure.
No adjustment required for topical application. Systemic absorption is minimal; however, in severe renal impairment (GFR <30 m L/min), use caution due to potential systemic corticosteroid effects.
Child-Pugh Class A and B: No dosage adjustment recommended. Child-Pugh Class C: Contraindicated.
No specific adjustment for topical use. In Child-Pugh C cirrhosis, consider the risk of systemic corticosteroid accumulation; use with caution.
Indicated for children aged 5 years and older with asthma. For ages 5-11: one inhalation of 100 mcg/25 mcg once daily. For ages 12 and older: same as adult dosing.
Children >2 years: Apply a thin film to affected area twice daily for up to 7 days. Avoid prolonged use, occlusion, or application to large body surface areas. Safety in children <2 years not established.
No dose adjustment required for elderly patients. Use with caution due to increased risk of comorbidities and adverse effects.
Elderly patients: Use the lowest effective duration and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. Apply sparingly to limited areas.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Use only as additional therapy for patients not adequately controlled on a long-term asthma control medication or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
None
Increased risk of asthma-related death when used as monotherapy for asthma without inhaled corticosteroid,Candida infections of the mouth and pharynx,Pneumonia in patients with COPD,Adrenal insufficiency,Hypercorticism and adrenal suppression,Paradoxical bronchospasm,Hypersensitivity reactions including anaphylaxis,Cardiovascular effects like increased blood pressure and heart rate,Eosinophilic conditions,Reduced bone mineral density,Glaucoma and cataracts
Prolonged use may lead to systemic corticosteroid effects, including HPA axis suppression, Cushing's syndrome, and hyperglycemia.,Risk of secondary infection due to immunosuppression.,Local adverse reactions such as skin atrophy, striae, and perioral dermatitis.,Avoid use in diaper area or under occlusive dressings.
Status asthmaticus or acute episodes of COPD requiring intensive therapy,Primary treatment of acute asthma exacerbation,Severe hypersensitivity to milk proteins or any ingredient
Hypersensitivity to any component (hydrocortisone, iodoquinol, or sulfites).,Viral or fungal infections without appropriate antimicrobial coverage.,Immunocompromised patients (systemic use relative).,Pregnancy (category C, use only if benefit outweighs risk).
No specific food interactions reported. However, grapefruit juice may increase systemic exposure to fluticasone furoate via CYP3A4 inhibition; although clinical significance is low, avoid excessive grapefruit consumption. No dietary restrictions necessary.
No clinically significant food interactions are reported for topical hydrocortisone/pramoxine. No dietary restrictions necessary.
Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at high systemic exposures. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adrenal suppression with prolonged use; avoid high doses and prolonged exposure.
No data on drug excretion in human milk; M/P ratio unknown. Corticosteroids and LABAs are expected to be present in low concentrations. Caution if breastfeeding, especially in preterm infants. Consider alternative therapies.
Present in breast milk in low concentrations. M/P ratio not determined. Use with caution, especially with high doses or prolonged treatment; risk of infant adrenal suppression theoretical.
No specific dose adjustments required due to pregnancy-induced pharmacokinetic changes, but use lowest effective dose to maintain asthma control due to potential fetal risk.
No standard dose adjustments required for pregnancy-related pharmacokinetic changes. Use lowest effective dose for shortest duration. Avoid high-dose or prolonged use in pregnancy.
Breo Ellipta (fluticasone furoate/vilanterol) is an ICS/LABA combination indicated for maintenance treatment of COPD and asthma. It is not for acute bronchospasm. The ELLIPTA inhaler is a once-daily, dry powder inhaler; each actuation delivers a fixed dose. Rinse mouth with water after use without swallowing to reduce oral candidiasis. Monitor for pneumonia in COPD patients. In asthma, it is not indicated for patients under 18 years; for COPD, use only in patients with a history of exacerbations. Do not discontinue abruptly.
AEROSEB-HC is a combination aerosol foam containing hydrocortisone acetate 1% and pramoxine hydrochloride 1% for topical use. It is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly in anogenital areas. The foam formulation enhances penetration and is less messy than ointments. Advise patients to avoid contact with eyes and mucous membranes. Use with caution in patients with skin infections or atrophy. Prolonged use in intertriginous areas may increase risk of local and systemic adverse effects.
Use exactly as prescribed; it is not a rescue inhaler for sudden breathing problems.,Rinse mouth with water after each dose without swallowing to prevent oral thrush.,Do not stop taking this medication without consulting your doctor; stopping can worsen breathing.,Tell your doctor if you have any signs of infection, pneumonia, or worsening breathing.,Store the inhaler at room temperature away from moisture and heat; keep it closed when not in use.
Apply a small amount to the affected area as directed, usually 2-4 times daily.,Do not cover the area with bandages or dressings unless instructed by your doctor.,Avoid use on broken skin, open wounds, or infected areas unless specifically prescribed.,Do not use for more than 2 weeks without medical supervision, especially in the anogenital region.,If symptoms do not improve or worsen, contact your healthcare provider.,Keep away from eyes, mouth, and other mucous membranes.,Wash hands after applying unless treating hands.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BREO ELLIPTA vs AEROSEB-HC, answered by our medical review team.
BREO ELLIPTA is a Corticosteroid/Beta-2 Agonist Combination that works by Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.. AEROSEB-HC is a Topical Corticosteroid that works by AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BREO ELLIPTA and AEROSEB-HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BREO ELLIPTA is: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.. The standard adult dose of AEROSEB-HC is: AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BREO ELLIPTA and AEROSEB-HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BREO ELLIPTA is classified as Category C. Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at. AEROSEB-HC is classified as Category C. FDA Pregnancy Category C. First trimester: limited data, no increased risk of major malformations identified in small studies. Second and third trimesters: potential for fetal adre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.